The novel MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of melanomas harboring the BRAF V600E mutation in vitro and in vivo

被引：0
|
作者：
Haass, N. K. [1 ]
Smalley, K. S. [1 ]
Sproesser, K. [1 ]
Contractor, R. [1 ]
Herlyn, M. [1 ]
机构：
[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2007年 / 127卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
931
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [1] Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244).
    Doyle, MP
    Yeh, TC
    Suzy, B
    Morrow, M
    Lee, PA
    Hughes, AM
    Cartlidge, S
    Wallace, E
    Lyssikatos, J
    Eckhardt, SG
    Winkler, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 210S - 210S
  • [2] Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Balagula, Yevgeniy
    Huston, Katherine Barth
    Busam, Klaus J.
    Lacouture, Mario E.
    Chapman, Paul B.
    Myskowski, Patricia L.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1114 - 1121
  • [3] Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
    Yevgeniy Balagula
    Katherine Barth Huston
    Klaus J. Busam
    Mario E. Lacouture
    Paul B. Chapman
    Patricia L. Myskowski
    Investigational New Drugs, 2011, 29 : 1114 - 1121
  • [4] Combination studies in vitro and in vivo with gefitinib (IRESSA) and the MEK 1/2 inhibitor AZD6244 (ARRY142886).
    Cockerill, M
    Logie, A
    Speake, G
    Beck, S
    Cartlidge, S
    Smith, PD
    Davies, B
    Hickinson, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8991S - 8991S
  • [5] A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
    Holkova, Beata
    Zingone, Adriana
    Kmieciak, Maciej
    Bose, Prithviraj
    Badros, Ashraf Z.
    Voorhees, Peter M.
    Baz, Rachid
    Korde, Neha
    Lin, Hui-Yi
    Chen, Jin-Qiu
    Herrmann, Michelle
    Xi, Liqiang
    Raffeld, Mark
    Zhao, Xiuhua
    Wan, Wen
    Tombes, Mary Beth
    Shrader, Ellen
    Weir-Wiggins, Caryn
    Sankala, Heidi
    Hogan, Kevin T.
    Doyle, Austin
    Annunziata, Christina M.
    Wellons, Martha
    Roberts, John D.
    Sullivan, Daniel
    Landgren, Ola
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1067 - 1075
  • [6] Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
    Catalanotti, Federica
    Solit, David B.
    Pulitzer, Melissa P.
    Berger, Michael F.
    Scott, Sasinya N.
    Iyriboz, Tunc
    Lacouture, Mario E.
    Panageas, Katherine S.
    Wolchok, Jedd D.
    Carvajal, Richard D.
    Schwartz, Gary K.
    Rosen, Neal
    Chapman, Paul B.
    CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2257 - 2264
  • [7] Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours
    Desar, Ingrid M. E.
    Bovenschen, H. Jorn
    Timmer-Bonte, Anja J. N. H.
    Cantarini, Mireille V.
    van der Graaf, Winette T. A.
    van Rossum, Michelle M.
    van Herpen, Carla M. L.
    ACTA ONCOLOGICA, 2010, 49 (01) : 113 - 116
  • [8] Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
    M Beloueche-Babari
    Y Jamin
    V Arunan
    S Walker-Samuel
    M Revill
    P D Smith
    J Halliday
    J C Waterton
    H Barjat
    P Workman
    M O Leach
    S P Robinson
    British Journal of Cancer, 2013, 109 : 1562 - 1569
  • [9] Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
    Beloueche-Babari, M.
    Jamin, Y.
    Arunan, V.
    Walker-Samuel, S.
    Revill, M.
    Smith, P. D.
    Halliday, J.
    Waterton, J. C.
    Barjat, H.
    Workman, P.
    Leach, M. O.
    Robinson, S. P.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1562 - 1569
  • [10] MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
    Takahashi, Osamu
    Komaki, Ritsuko
    Smith, Paul D.
    Ryan, Anderson
    Jurgensmeier, Juliane M.
    Welsh, James W.
    Jacoby, Joerg J.
    Hosho, Keiko
    Korshunova, Maria, V
    Erez, Baruch
    Herbst, Roy S.
    O'Reilly, Michael S.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S593 - S593
12345